(photo courtesy of Multiple Myeloma Hub)
Each year a group of the top myeloma specialists review the abstracts presented at the American Society of Hematology and pick their favorites. This has been so helpful to all those of us who attend this annual meeting. It is so overpowering for a patient, patient advocate, or health care professionals to whittle down the avalanche of information into manageable segments which are most relevant to the myeloma care community.
And each year Dr. Mike Thompson has been so kind as to tabulate the picks from the myeloma specialists into a easily understandable table. Dr. Thompson will be completing this work in next few days, and at that time Myeloma Crowd will be publishing this document. In addition, some of these myeloma specialists have gone the extra step, and provided an excellent explanation as to why they have chosen their most important TOP FIVE.
Dr. Vincent Rajkumar has been doing this for several years, and he has again this year. Each year he has chosen to list his favorites, but only those abstracts which have not been reported on previously. This is his list of the most significant new initiatives for #ASH20. As in the past, he left out many great studies where similar results were already presented or published before. And his focus was for clinical relevance, impact, and methodology.
This is a novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) & CD3 shows activity in relapsed refractory myeloma. High response rates (78%) @ 20-180 mcg/kg dose levels.
BFCR4350A is a novel bi-specific antibody targeting FcRH5. FcRH5 is universally expressed on plasma cells) and CD3 shows clinical activity in relapsed refractory myeloma.
Long term results of IFM 2009 trial shows similar overall survival after 8 years follow up between early vs delayed transplant in the modern era with VRd therapy. Particularly important info at time of COVID.
Bi allelic loss of BCMA locus at 16p. Important work.
Abstract 721 Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
First in human results with Anti BCMA ALLO-647 shows clinical activity in myeloma. 5 of 15 responses.
Thank You Dr. Rajkumar for your continued support for the myeloma care and patient community.
about the author
Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1